Voloridge Investment Management LLC Sells 156,662 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA)

Voloridge Investment Management LLC cut its holdings in Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 34.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 293,159 shares of the company's stock after selling 156,662 shares during the quarter. Voloridge Investment Management LLC owned approximately 0.13% of Sana Biotechnology worth $478,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Vident Advisory LLC grew its position in shares of Sana Biotechnology by 42.3% in the 4th quarter. Vident Advisory LLC now owns 43,291 shares of the company's stock worth $71,000 after buying an additional 12,861 shares during the period. Squarepoint Ops LLC grew its position in Sana Biotechnology by 45.3% during the 4th quarter. Squarepoint Ops LLC now owns 178,431 shares of the company's stock valued at $291,000 after purchasing an additional 55,625 shares during the last quarter. Two Sigma Advisers LP grew its position in Sana Biotechnology by 677.0% during the 4th quarter. Two Sigma Advisers LP now owns 209,000 shares of the company's stock valued at $341,000 after purchasing an additional 182,100 shares during the last quarter. Two Sigma Investments LP grew its position in Sana Biotechnology by 228.4% during the 4th quarter. Two Sigma Investments LP now owns 480,298 shares of the company's stock valued at $783,000 after purchasing an additional 334,042 shares during the last quarter. Finally, ProShare Advisors LLC boosted its holdings in shares of Sana Biotechnology by 25.4% during the 4th quarter. ProShare Advisors LLC now owns 47,808 shares of the company's stock valued at $78,000 after acquiring an additional 9,679 shares during the last quarter. 88.23% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SANA has been the topic of several recent research reports. HC Wainwright reiterated a "buy" rating and issued a $11.00 price objective on shares of Sana Biotechnology in a research note on Thursday, April 24th. Citizens Jmp raised shares of Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 price objective for the company in a report on Tuesday, March 18th. Finally, Jefferies Financial Group assumed coverage on shares of Sana Biotechnology in a report on Friday, March 14th. They set a "buy" rating and a $7.00 price objective for the company. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $10.80.

Sana Biotechnology Trading Up 6.4%

Shares of SANA traded up $0.14 during trading hours on Tuesday, reaching $2.34. 2,822,063 shares of the company traded hands, compared to its average volume of 3,482,411. The stock's fifty day moving average price is $1.78 and its 200 day moving average price is $2.33. The firm has a market cap of $527.62 million, a price-to-earnings ratio of -1.67 and a beta of 1.75. Sana Biotechnology, Inc. has a 12-month low of $1.26 and a 12-month high of $7.91.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.02. On average, research analysts forecast that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.